B7-H3与前列腺癌雄激素受体、免疫通路及不良结局的相关性:一项基于表达的分析
基于2781例前列腺切除组织芯片表达数据,B7-H3 mRNA表达与更高Gleason评分、肿瘤分期及去势抵抗转移性疾病正相关;高表达与转移和前列腺癌特异性死亡相关但多因素分析未显著。B7-H3与ERG阳性(r=0.99)及AR表达(r=0.36)相关,ChIP显示B7-H3上游存在AR结合位点,LNCaP中雄激素降低B7-H3表达,提示可能受AR直接调控。
要点
- B7-H3 mRNA表达与更高Gleason评分、肿瘤分期及去势抵抗转移性疾病正相关。
- 高B7-H3表达与转移及前列腺癌特异性死亡相关,但多因素分析未达显著。
- B7-H3与ERG阳性(r=0.99)及AR表达(r=0.36)相关,LNCaP中雄激素降低其表达。
核心结论
- 在前列腺切除队列中,较高的B7-H3表达与Gleason分级、前列腺癌分期及不良肿瘤学结局相关。
- B7-H3表达似乎与雄激素信号及免疫反应组相关。
研究设计与样本
- 对2781例患者的前列腺切除组织使用Affymetrix HuEx 1.0 ST微阵列进行表达谱分析。
- 采用成对比较识别B7-H3表达与临床病理变量的显著关联,并用生存分析评估B7-H3的预后意义。
- 采用Pearson相关分析评估B7-H3表达与分子亚型及单个转录本的关系。
- 通过染色质免疫沉淀(ChIP)确定雄激素受体(AR)在B7-H3位点的占据,并在LNCaP细胞系中用定量逆转录PCR评估雄激素依赖的B7-H3表达变化。
- 查询Oncomine以评估转移性疾病中B7-H3的表达。
主要发现
- B7-H3 mRNA表达与更高Gleason评分(P<0.001)、肿瘤分期(P<0.001)及去势抵抗转移性疾病(P<0.0001)正相关。
- 高B7-H3表达与转移发生及前列腺癌特异性死亡相关,但在多因素分析中不显著。
- B7-H3表达与ERG阳性疾病(r=0.99)及AR表达(r=0.36)相关。
- ChIP显示B7-H3上游存在AR结合位点,且雄激素的存在降低LNCaP中B7-H3表达,提示可能存在AR直接调控。
- 基因集富集分析显示B7-H3与雄激素信号及免疫调节通路相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules, has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism of action remain unclear. B7-H3 protein expression correlates with prostate cancer outcomes, and humanized monoclonal antibodies (that is, enoblituzumab) are currently being investigated for therapeutic use. Here we used genomic expression data to examine the relationship between B7-H3 mRNA expression and prostate cancer. METHODS: Prostatectomy tissue from 2781 patients were profiled using the Affymetrix HuEx 1.0 ST microarray. Pairwise comparisons were used to identify significant associations between B7-H3 expression and clinicopathologic variables, and survival analyses were used to evaluate the prognostic significance of B7-H3. Pearson's correlation analyses were performed to assess the relationship of B7-H3 expression with molecular subtypes and individual transcripts. Androgen receptor (AR) occupancy at the B7-H3 locus was determined using chromatin immunoprecipitation (ChIP), and androgen-dependent expression changes in B7-H3 was evaluated by quantitative reverse transcription PCR in LNCaP cell lines. Oncomine was queried to evaluate B7-H3 expression in metastatic disease. RESULTS: B7-H3 mRNA expression was positively associated with higher Gleason score (P<0.001), tumor stage (P<0.001), and castrate resistant metastatic disease (P<0.0001). High B7-H3 expression correlated with the development of metastasis and prostate cancer specific mortality, but this was not significant on multi-variable analysis. B7-H3 expression correlated with ERG-positive disease (r=0.99) and AR expression (r=0.36). ChIP revealed an AR-binding site upstream of B7-H3, and the presence of androgens decreased B7-H3 expression in LNCaP suggesting potential direct AR regulation. Gene set enrichment analysis demonstrated an association of B7-H3 with androgen signaling as well as immune regulatory pathways. CONCLUSIONS: Higher B7-H3 expression correlates with Gleason grade, prostate cancer stage and poor oncologic outcomes in prostatectomy cohorts. B7-H3 expression appears to be related to androgen signaling as well as the immune reactome.
引用
- Benzon B, Zhao SG, Haffner MC, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2016. PMID: 27801901. doi:10.1038/pcan.2016.49
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。